ANDA suitability petition for indomethacin constant-release 75 mg tabs was denied by FDA. Verex had filed the petition in January. FDA Office of Drug Standards Div. Director Peter Rheinstein told the firm that investigations are needed to show the safety and efficacy of the proposed product because its "controlled-release mechanism differs significantiy from" the referenced product Indocin SR. Rheinstein explained that "Indocin SR is not a constant release product as referred to in your petition," because if "has kinetic characteristics such that it releases 25 mg of indomethacin initially and then subsequently releases 50 mg more".
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.